Moods Disorders Completed Phase 3 Trials for Quetiapine (DB01224)

Also known as: Mood Disorders / Mood Disorder

IndicationStatusPhase
DBCOND0058256 (Moods Disorders)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01727726A Study of Flexible-dose Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus TrialTreatment
NCT00221468A Study of Quetiapine for the Treatment of Mood Disorders in AdolescentsTreatment
NCT00309699A Study to Evaluate the Efficacy and Safety of Flexible Doses of Extended-release (ER) Paliperidone Compared With Flexible Doses of Quetiapine and Placebo in Patients With Bipolar I DisorderTreatment